Biolab Sanus Farmaceutica, Epirus, Eurofarma Laboratorios deal

Epirus partnered with Orygen Biotecnologia Ltda. - a JV between Eurofarma and Biolab Sanus - to develop and commercialize biosimilars in Brazil. The deal includes Epirus' BOW015, a biosimilar of Remicade infliximab, as well as two additional undisclosed biosimilar mAbs from Epirus. Epirus will be primarily responsible for clinical development and will have rights to the products outside of Brazil. Orygen will have rights to the biosimilars in Brazil. Epirus is eligible for up to $275 million in an undisclosed upfront payment, milestones, royalties and service-based fees. ...